Literature DB >> 34304374

Olanzapine/Samidorphan: First Approval.

Julia Paik1.   

Abstract

Samidorphan, which was developed by Alkermes, is an opioid receptor antagonist that has been co-formulated with olanzapine into a single-dose oral tablet to mitigate the risk of weight gain while providing the therapeutic effect of olanzapine. Olanzapine/samidorphan (LYBALVI™) was recently approved in the USA for the treatment of schizophrenia and bipolar I disorder. This article summarizes the milestones in the development of samidorphan leading to this first approval of olanzapine/samidorphan.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34304374     DOI： 10.1007/s40265-021-01568-0

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  1 in total

1.  Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.

Authors:  Sergey Yagoda; Christine Graham; Adam Simmons; Christina Arevalo; Ying Jiang; David McDonnell
Journal:  CNS Spectr       Date:  2020-05-12       Impact factor: 3.790
  1 in total
  4 in total

Review 1.  Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review.

Authors:  Hannah W Haddad; Elena Boardman; Brooke Williams; Rama Mouhaffel; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-04-25

Review 2.  A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.

Authors:  Gizem Kayki-Mutlu; Zinnet Sevval Aksoyalp; Leszek Wojnowski; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-11       Impact factor: 3.195

Review 3.  Neuroplastin in Neuropsychiatric Diseases.

Authors:  Xiao Lin; Yi Liang; Rodrigo Herrera-Molina; Dirk Montag
Journal:  Genes (Basel)       Date:  2021-09-26       Impact factor: 4.096

Review 4.  Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials.

Authors:  Syeda Tayyaba Rehan; Abdul Hannan Siddiqui; Zayeema Khan; Laiba Imran; Abdul Ahad Syed; Muhammad Junaid Tahir; Zahra Jassani; Manjeet Singh; Muhammad Sohaib Asghar; Ali Ahmed
Journal:  Ann Med Surg (Lond)       Date:  2022-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.